Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 03 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
- 03 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.
- 10 Jun 2017 Biomarkers information updated
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History